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Objectives By examining the distribution of coronary artery calcium (CAC) levels across Framingham risk score (FRS) strata
in a large, multiethnic, community-based sample of men and women, we sought to determine if lower-risk per-
sons could benefit from CAC screening.
Background The 10-year FRS and CAC levels are predictors of coronary heart disease. A CAC level of 300 or more is associ-
ated with the highest risk for coronary heart disease even in low-risk persons (FRS, 10%); however, expert
groups have suggested CAC screening only in intermediate-risk groups (FRS, 10% to 20%).
Methods We included 5,660 Multi-Ethnic Study of Atherosclerosis participants. The number needed to screen (number of
people that need to be screened to detect 1 person with CAC level above the specified cutoff point) was used to
assess the yield of screening for CAC. CAC prevalence was compared across FRS strata using chi-square tests.
Results CAC levels of more than 0, of 100 or more, and of 300 or more were present in 46.4%, 20.6%, and 10.1% of
participants, respectively. The prevalence and amount of CAC increased with higher FRS. A CAC level of 300 or
more was observed in 1.7% and 4.4% of those with FRS of 0% to 2.5% and of 2.6% to 5%, respectively (number
needed to screen, 59.7 and 22.7, respectively). Likewise, a CAC level of 300 or more was observed in 24% and
30% of those with FRS of 15.1% to 20% and more than 20%, respectively (number needed to screen, 4.2 and
3.3, respectively). Trends were similar when stratified by age, sex, and race or ethnicity.
Conclusions Our study suggests that in very low-risk individuals (FRS 5%), the yield of screening and probability of identify-
ing persons with clinically significant levels of CAC is low, but becomes greater in low- and intermediate-risk per-
sons (FRS 5.1% to 20%). (J Am Coll Cardiol 2011;57:1838–45) © 2011 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.11.053In the current clinical practice of preventive cardiology, the
intensity of treatment is matched to the severity of the patient’s
overall (global) cardiovascular risk status based on the principle
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accepted November 1, 2010.that the highest-risk patients will benefit the most from drug
treatments, with less absolute benefit for lower-risk patients.
The Framingham risk score (FRS) is considered a useful tool
in the estimation of 10-year risk of coronary heart disease
(CHD), but fails to identify many people destined to have a
CHD event (1). Thus, additional tests of cardiovascular
risk such as coronary artery calcium (CAC) scoring have
been evaluated as possible ways to improve global CHD
risk assessment. CAC has been shown to provide incre-
mental CHD risk prediction beyond traditional risk
factors, and patients with advanced CAC burden (CAC
scores: 300 or 400) have the greatest risk (2– 6).
Although proposed as an adjunctive tool for risk assess-
ment, CAC scoring has not been recommended for wide-
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May 3, 2011:1838–45 CAC Distribution by FRS Strata in MESAspread population screening in recent consensus statements
(5,7,8) and instead has been regarded as most promising in
modifying risk assessment primarily in intermediate-risk
patients in whom the estimated 10-year CHD risk is
between 10% and 20% by FRS (5,8). Recent data from the
Multi-Ethnic Study of Atherosclerosis (MESA) suggested that
in low-risk women, a very high CAC score (300) was
associated with an adjusted hazard ratio of 8 for major
coronary events compared with those without detectable
CAC (3). However, whether lower-risk patients might
benefit from CAC testing is not yet answered.
Although a few studies have examined the relationship
between FRS and CAC prevalence and amount (2,9–14), it
is still not yet known whether additional CAC testing in
low- to intermediate-risk patients would be a useful way to
find additional high-risk patients who might merit more
intensive risk factor treatments. These previous studies have
been limited by small sample size, referral-based samples,
homogenous racial and sex compositions, and self-report of
risk factors, with sparse data on stratification by age, sex and
race or ethnicity. In addition, it is unclear how many people
at selected levels of risk would require screening to detect 1
person with a CAC level of 300 or more.
The aim of the present study was to ascertain the
prevalence and distribution of CAC across FRS in a large,
multiethnic, multicenter, community-based sample of men
and women stratified by age, sex, and race or ethnicity.
Based on these relationships, the yield of screening, and
therefore FRS ranges where CAC scoring might be bene-
ficial in risk assessment, may become apparent and may aid
further risk stratification for the large number of asymptom-
atic individuals predicted to be at low or intermediate
10-year risk by traditional risk factors alone.
Methods
The MESA is a prospective cohort study examining mea-
sures of subclinical atherosclerosis, progression of subclinical
atherosclerosis, and conversion to clinical events. Details of
the study design, as well as inclusion and exclusion criteria
and baseline characteristics, have been described previously
(15). Briefly, at baseline, the cohort included 6,814 partic-
ipants (3,213 men and 3,601 women) 45 to 84 years of age
from 4 different racial or ethnic groups (38% white, 28%
black, 22% Hispanic, and 12% Chinese) in 6 U.S. commu-
nities, including Baltimore, Maryland; Chicago, Illinois;
Forsyth, North Carolina; Los Angeles, California; New
York, New York; and St. Paul, Minnesota. The participants
were free of clinical cardiovascular disease at first examina-
tion (July 2000 through August 2002).
For the current study, we included men and women 79
years of age or younger at baseline (n 6,526) because FRS
could not be calculated in individuals older than 79 years of
age. Participants with diabetes were excluded from our
analyses (n 811) because they were considered high risk in
urrent National Cholesterol Education Program Adult wreatment Panel III guidelines
16), and our study focused on
valuating yield of screening in
ndividuals at lower risk. Finally,
5 additional participants were
xcluded because of missing FRS
quation covariates (n  7) and
bsence of measured CAC (n 
8). Baseline examination, labo-
atory data, and cardiac com-
uted tomography methods have
een described elsewhere (6,15).
efinitions. Body mass index was defined as weight in
ilograms divided by height in meters squared. Presence or
bsence of family history of heart attack was determined at
aseline and was described further in detail during the
econd examination. Current smoking was defined as smok-
ng cigarettes within the past 30 days. Medication use was
erived from medication lists and clinical staff entry of
rescribed medications. Aspirin use was defined as 3 days or
ore per week at baseline.
Agatston CAC measurement and scoring have been
escribed previously (17). There was excellent agreement
etween and within readers for presence and amount of
alcified plaque (kappa:0.90 and0.99, respectively). For
his study, Agatston CAC scores were obtained from the
aseline MESA examination 1 (2000 through 2002). CAC
cores were categorized as CAC of more than 0, 100 or
ore, or 300 or more. Concurrent FRS 10-year risk for
HD (16) was calculated and stratified as follows: 0% to
.5%, 2.6% to 5%, 5.1% to 7.5%, 7.6% to 10%, 10.1% to
5%, 15.1% to 20%, and more than 20%. We chose these
efined CAC cutoff points rather than mutually exclusive
AC categories because the study aimed to examine screen-
ng, rather than risk prediction thresholds.
tatistical analysis. All analyses were performed using
AS software version 9.2 (SAS Institute, Cary, North
arolina). A 2-tailed value of p  0.05 was considered
tatistically significant. The 10-year FRS estimates for all
articipants at examination 1 were calculated based on age,
otal and high-density lipoprotein cholesterol levels, current
moking status, systolic blood pressure, and the use of
ntihypertensive medication using the risk prediction func-
ions from the National Cholesterol Education Program
dult Treatment Panel III guidelines (16). Baseline char-
cteristics were compared according to FRS 10-year risk
ategories and by CAC classification using general linear
odels for continuous variables and cross-tabulations for
ategorical variables. The prevalence of CAC strata across
RS 10-year strata were compared using the chi-square test.
he comparison was assessed further after stratification by
ge, sex, and race. The yield of screening for CAC was
ssessed using the number needed to screen (NNS), which
as calculated by dividing the total number of participants
Abbreviations
and Acronyms
CAC  coronary artery
calcium
CHD  coronary heart
disease
FRS  Framingham risk
score(s)
NNS  number needed to
screenithin each FRS stratum by the number of people with
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CAC Distribution by FRS Strata in MESA May 3, 2011:1838–45CAC of more than 0, of 100 or more, or of 300 or more
within that FRS stratum. The NNS defines the number of
people who need to be screened to identify 1 individual with
a CAC value above the specified CAC cutoff point within
each FRS category. For the purposes of our study, CAC
amount is represented by median CAC scores within FRS
groups.
Multivariate analyses were carried out to determine the
relationship between CAC of 300 or more (advanced CAC)
and FRS distributions. The associations of 10-year FRS
levels with CAC of 300 or more were examined (separately)
using logistic regression models, and the multivariate-
adjusted odds ratios and their 95% confidence intervals were
assessed. Covariates included race or ethnic background,
Baseline Characteristics by Coronary Artery Calcium Score CategoTable 1 Baseline Characteristics by Coronary Artery Calcium S
Characteristics
Coro
0
(n  3,034)
>0
(n  2,626) p Value
<
(n 
Mean age (yrs) 57.4 8.8 65.0 9.0 0.01 59.2
Female 63.6 41.4 0.01
Race 0.01
White 35.8 47.8
Black 29.3 22.2
Chinese American 11.8 11.8
Hispanic 23.1 18.2
SBP (mm Hg) 121.4 20.2 129.1 20.9 0.01 123.3
DBP (mm Hg) 71.2 10.3 73.0 10.2 0.01 71.6
BMI (kg/m2) 28.0 5.5 28.1 5.2 0.58 28.1
Total cholesterol (mg/dl) 194.5 34.7 196 35.4 0.10 195
HDL cholesterol (mg/dl) 53.0 15.2 49.9 14.5 0.01 52.1
LDL cholesterol (mg/dl) 116.6 30.3 120.1 31.8 0.01 117.8
Current smoking 13.3 13.8 0.59
HTN treatment 23.0 36.1 0.01
Lipid treatment 9.6 19.6 0.01
Family history 35.5 46.0 0.01
Physical activity
(MET min/week)
927 2,714 1,055 3,076 0.09 977
Education 0.04
Less than high school 16.1 15.8
High school 16.3 19.1
College 48.4 45.6
Graduate school 19.3 19.5
Married 61.5 62.9 0.30
Annual income 0.01
$25,000 26.2 31.2
$25,000–$50,000 28.9 28.8
$50,000–$75,000 19 16.4
$75,000 25.9 23.6
Health insurance 74.2 69.0 0.01
Medications
Aspirin 13.5 23.9 0.01
ACEI/ARB 7.0 13.2 0.01
Beta-blocker 7.0 10.8 0.01
Nitrates 0.1 0.2 0.36
CCB 8.0 13.7 0.01
Values are mean  SD or %.
ACEI  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; BMI  body m
ipoprotein; HTN  hypertension; LDL  low-density lipoprotein; MET  metabolic equivalent; SBP  sysbody mass index, family history of heart attack, use of
aspirin, family income, education, health insurance, marital
status, beta blocker use, calcium channel blocker use, and
angiotensin-converting enzyme inhibitor or angiotensin re-
ceptor blocker use, as shown in Table 1. A model containing
these covariates plus strata of 10-year FRS covariates were
fitted to estimate their association. This model was chosen
based on known associations of certain racial or ethnic
groups with increased CAC, FRS, or both; risk factors
known to be associated with CHD, but not included in the
FRS model; and socioeconomic factors. We focused our
multivariate analysis on CAC of 300 or more because
advanced CAC (CAC score 300 or 400) has been
associated with the highest risk for CHD events (2–4,6,18).
n  5,660)Categories (n  5,660)
rtery Calcium Score Categories
7)
>100
(n  1,163) p Value
<300
(n  5,086)
>300
(n  574) p Value
67.8 8.1 0.01 60.3 9.4 68.9 7.6 0.01
34.4 0.01 56.1 28.4 0.01
0.01 0.01
55.1 39.4 59.1
9.4 26.8 19.0
19.8 12.4 6.5
15.7 21.4 15.5
4 131.6 21.3 0.01 124.1 20.6 133.2 21.5 0.01
3 73.3 10.1 0.01 71.8 10.3 74 10 0.01
28.1 5.0 0.63 28.1 5.4 28.1 4.7 0.96
0 195.8 35.3 0.50 195.2 35.0 195.1 35.1 0.95
0 49.8 14.7 0.01 51.8 15.0 49.6 14.5 0.01
9 120.0 31.6 0.03 118.1 31.0 119.1 31.5 0.46
13.2 0.79 13.4 13.9 0.73
41.2 0.01 27.5 43.2 0.01
22.4 0.01 13.2 23.3 0.01
49.9 0.01 39.0 52.6 0.01
37 1,022 2,691 0.63 970 2,893 1,135 2,837 0.19
0.01 0.51
13.9 16.1 14.5
20.3 17.4 19.2
45.5 47.2 46.0
20.3 19.3 20.4
62.6 0.73 62.1 62.9 0.70
0.02 0.32
32.4 28.1 31.9
28.0 29.0 27.7
16.5 17.9 17.0
23.1 25.0 23.4
67.6 0.01 72.2 67.8 0.02
29.6 0.01 16.7 32.9 0.01
16.2 0.01 8.9 18.1 0.01
12.0 0.01 8.4 12.2 0.01
0.2 0.76 0.2 0.0 0.34
15 0.01 10.1 15.5 0.01ries (core
nary A
100
4,49
 9.2
58.2
37.8
12.4
27.7
22.2
 20.
 10.
 5.5
 35.
 15.
 30.
13.5
25.9
12.2
37.9
 2,9
16.5
16.9
47.5
19.2
62.0
27.6
29.1
18.1
25.3
72.9
15.4
8.2
8.0
0.1
9.5ass index; CCB  calcium channel blocker; DBP  diastolic blood pressure; HDL  high-density
tolic blood pressure.
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Baseline characteristics. Our study sample was made up of
a total of 5,660 MESA men and women (mean age: 60.9
years, 53% women) from 4 different racial or ethnic groups
(41% white, 26% black, 12% Chinese, and 21% Hispanic).
There were significant differences in most traditional risk
factors, sociodemographic factors, and medication use be-
tween participants using all 3 CAC cutoff points (CAC 0
vs. CAC 0, CAC100 vs. CAC100, and CAC300
s. CAC300) (Table 1). As expected, most of the baseline
haracteristics, including traditional cardiovascular risk fac-
ors, were significantly different across FRS strata (data not
hown).
istribution of CAC prevalence and amount compared
cross FRS strata. Table 2 displays the comparison of
CAC prevalence and amount using different cutoff points
across FRS strata. The median CAC scores (among those
with CAC 0) with interquartile ranges across FRS strata
also are shown. For the entire cohort, the median CAC
scores were greater with higher FRS (Spearman correlation
coefficient: 0.45, p  0.01). Similarly, CAC prevalence (for
each CAC cutoff point) increased with greater FRS (all p 
0.01 for trend) (Fig. 1). Within each CAC category, the
NNS to detect 1 participant with CAC of more than the
selected CAC cutoff point decreased with higher FRS
(Table 2). For example, among those with CAC of 300 or
more, the NNS decreased from 59.7 for FRS of 0% to 2.5% to
3.3 for FRS of more than 20%. Likewise, within each FRS
stratum, the NNS increased with increasing CAC severity
category. The pattern of results was similar when we used
CAC of 400 or more as the cutoff point for advanced CAC.
Data were stratified further by sex (Table 3), which
revealed that the prevalence of CAC of more than 0, of 100
or more, and of 300 or more and median CAC scores were
higher in women than in men for the lower FRS strata,
equivocal between men and women in the intermediate FRS
strata, and generally slightly higher in men than in women
for the higher FRS strata. Stratification by age (45 to 54
years, 55 to 64 years, and 65 to 79 years) generally followed
the same pattern as the overall cohort (data not shown),
with median CAC scores and prevalence of CAC of more
than 0, CAC of 100 or more, and CAC of 300 or more
increasing across advancing age groups. When stratified by
race or ethnicity, whites exhibited the highest median CAC
scores and the highest prevalence of CAC of more than 0,
CAC of 100 or more, and CAC of 300 or more in each FRS
stratum, with higher disparity between whites and the rest
of the racial or ethnic groups as CAC severity increased.
Univariate and multivariate analyses for odds of advanced
CAC (CAC >300) across FRS strata. Compared with FRS
f more than 20% as the referent group, the unadjusted odds
atios for CAC of 300 of more were significantly lower with
ower FRS and increased steadily with higher FRS (Table
). The multivariate odds ratios for CAC across FRS strata
ollowed the same pattern, with significantly increasing odds CA T
M C N C N C N
Va
lu C
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CAC Distribution by FRS Strata in MESA May 3, 2011:1838–45ratios for CAC of 300 or more with greater FRS, even after
adjusting for race or ethnicity, socioeconomic factors, as well
as other cardiovascular risk factors not included in the FRS
equation.
Discussion
Major findings. We found a significant direct relationship
between 10-year predicted FRS and CAC prevalence and
amount such that the lower FRS risk strata had lower
prevalence of CAC and lower median CAC scores. With
higher FRS strata, prevalence of CAC and CAC burden
increased in a stepwise fashion and demonstrated good
linear correlation. For the overall cohort, among those with
FRS of 0.0% to 2.5% and 2.6% to 5.0%, only 1.7% and 4.4%
of our study population, respectively, had CAC scores of
300 or more. However, 24% and 30% of participants had
CAC scores of 300 or more in the 15.1% to 20.0% and more
than 20% FRS strata, respectively. Similar to the trend in
CAC prevalence, the yield of screening for CAC decreased
in a stepwise fashion across greater FRS strata: the numbers
of people who needed to be screened to identify 1 person
with CAC level of 300 or more (NNS for CAC: 300)
were 59.7 and 22.7 in individuals with FRS of 0.0% to 2.5%
and 2.6% to 5.0%, respectively, compared with 4.2 and 3.3
in those with FRS of 15.1% to 20.0% and more than 20%,
respectively. Data remained essentially unchanged when
stratified by age, sex, or race or ethnicity. Likewise, multi-
variate analysis showed significantly increasing odds for
CAC level of 300 or more with greater FRS strata.
Potential clinical implications. CAC score is related di-
Figure 1 Coronary Calcium Prevalence by Framingham Risk Sc
Bar graph showing the prevalence of categories of coronary artery calcium (CAC) s
compared across 10-year Framingham risk score (FRS) strata.rectly to incidence of CHD events such that advanced CACburden (CAC300 or 400) poses the highest risk for CHD
events (2–4,6,18). As such, we focus our discussion on the
association of FRS with CAC of 300 or more, which is the
definition of advanced CAC used in the current study.
According to current National Cholesterol Education
Program Adult Treatment Panel III guidelines (16), indi-
viduals with an FRS of more than 20% are considered to be
at high risk for CHD events and should be managed
appropriately with drug therapy and lifestyle modifications.
Therefore, no further risk assessment is considered neces-
sary in these individuals. However, for the large proportion
of low- to intermediate-risk populations, the intervention
goals are defined less clearly and may be difficult to interpret
in the absence of additional information such as that
provided by a CAC score. Hence, our data address the
potential for modification of risk category in the predicted
low- and intermediate-risk patient populations. The high
rate of CAC of 300 or more in the FRS category with
predicted risk of 15.1% to 20.0% suggests a group at high
risk for CHD who particularly may benefit from screening
for CAC of 300 or more to aid further risk factor interven-
tions, especially in situations where there is uncertainty
regarding the use of drug therapy. However, the low rate of
CAC of 300 or more in the lowest FRS risk categories (FRS
0% to 5%) suggests that this group is far less likely to yield
a high CAC score on further CAC testing.
For this study, we chose the NNS as a tool to help
evaluate potential thresholds or the yield of screening for
CAC across FRS strata. The NNS (an extension of the
concept of the number needed to treat) has been described
(CAC) (0, 100, and 300)ore
coresin the literature as the number of people who need to be
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May 3, 2011:1838–45 CAC Distribution by FRS Strata in MESAscreened to prevent 1 death or 1 adverse event (19). This
initial definition has been modified in the literature (20,21),
but to our knowledge has not been used in screening for
subclinical CHD. For the purposes of this study, NNS was
defined as the number of individuals who would have to be
screened to find 1 person with CAC of more than 0, 100 or
more, or 300 or more, depending on the CAC category.
The NNS in this case weighs the yield of screening for
CAC within each FRS category from a public health
perspective. Among those with CAC of 300 or more in our
study, the NNS was 59.7 and 22.7 for individuals with FRS
of 0.0% to 2.5% and 2.6% to 5.0%, respectively, and 4.2 and
3.3 for those with FRS of 15.1% to 20.0% and more than
20%, respectively. This represents an 18-fold difference in
NNS for CAC of 300 or more (absolute difference of 56)
between the lowest-risk FRS stratum (FRS 0.0% to 2.5%)
and the high-risk stratum (FRS 20%). This difference
remained reasonably large—a 7-fold difference (absolute
difference of 19) between the subsequent lowest FRS risk
stratum (FRS 2.6% to 5.0%) and the high-risk stratum, but
became much smaller beyond that. It likely suggests a
substantial difference (with minimal yield of screening) in
the very low-risk groups (FRS 0% to 5%) compared with the
higher risk groups. To put our NNS findings in context, it
should be noted that among those screened, the NNS to
prevent 1 death secondary to abdominal aortic aneurysm
was 20.4 in the Multicentre Aneurysm Screening Study
(22). This study used abdominal ultrasound to evaluate the
benefit of screening for abdominal aortic aneurysms. Future
studies using mortality and cardiovascular events data in the
distribution of CAC by FRS strata to evaluate the concept
of the NNS for CAC screening clearly are warranted.
Taken together, our prevalence and NNS data suggest
the benefit of CAC testing for further risk stratification in
asymptomatic low-risk (FRS of 5.1% to 10.0%) and
intermediate-risk (FRS 10.1% to 20.0%) persons. Based on
empiric observations, this is in agreement with several
recommendations for the use of CAC testing for further risk
stratification in asymptomatic people who are found to be at
intermediate risk (FRS 10% to 20%) (5,8). Our study data
Univariate and Multivariable Odds Ratios and 95% CIsfor CAC Score >300 by Framingham Risk Score StrataTable 4 Univariate and Multivari ble Od s Ratios and 95% CIsfor CAC Score >300 by Framingham Risk Score Strata
FRS Categories
Odds Ratios (95% CI) for CAC >300
Unadjusted Adjusted*
20% 1.0 1.0
15% to 20% 0.73 (0.53 to 1.00) 0.68 (0.48 to 0.95)
10.1% to 15.0% 0.42 (0.30 to 0.60) 0.39 (0.27 to 0.57)
7.6% to 10.0% 0.35 (0.25 to 0.49) 0.32 (0.22 to 0.46)
5.0% to 7.5% 0.19 (0.12 to 0.29) 0.19 (0.12 to 0.31)
2.6% to 5.0% 0.11 (0.07 to 0.16) 0.10 (0.06 to 0.15)
0.0% to 2.5% 0.04 (0.03 to 0.06) 0.04 (0.02 to 0.06)
*Model adjusted for race/ethnicity, body mass index, family history of heart attack, aspirin use,
education, marital status, income, and health insurance.
CI  confidence interval; FRS  Framingham risk score; other abbreviation as in Table 2.suggest that CAC measurement should be carried outCA T
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rather than in isolation, and provides support for avoidance
of radiation exposure as well as time, money, and effort
spent on CAC measurement and scoring for clinical guid-
ance in very low-risk patients.
Other findings. The patterns of CAC distribution differed
by sex. With lower FRS, women exhibited higher CAC
prevalence and amount than men. The prevalence of CAC
became similar in both sexes at intermediate FRS scores and
switched at higher FRS so that men (as would be expected)
showed higher CAC prevalence and amount than women.
This pattern is likely because at any given age, FRS is
significantly lower for women than men. Consequently,
there are more women than men at lower FRS stratum,
because most women remain at low calculated FRS 10-year
risk until 70 years of age (23–25). Also, our analysis was
truncated at age 79 years. Men have higher FRS than
women regardless of age, and therefore are distributed more
evenly across the spectrum of FRS strata. They therefore are
much of the higher FRS strata relative to women.
As expected, CAC amount and prevalence increased
across FRS strata and with increasing age, which is pur-
ported to be the best surrogate marker for accumulated
exposure to CHD risk factors (13). Similar to findings in
other studies (26–30), the highest prevalence and severity of
CAC was observed among white persons in our study,
whereas the lowest prevalence was observed among black
persons.
CAC of 400 or more is suggested as a reasonable
definition of advanced CAC (5). However, because we had
few participants in the CAC of 400 or more category, we
used CAC of 300 or more, as used in other studies (2,6), in
defining advanced CAC for this study. Regardless, in our
analysis, the distribution of CAC by FRS strata and the
trend for yield of screening for CAC of 400 or more within
FRS strata were similar to what we observed when we
defined advanced CAC using CAC of 300 or more as the
cutoff point.
Study limitations. Because of the small numbers of par-
ticipants in each age, sex, and race or ethnicity category, we
could not make meaningful assessments of the findings
using simultaneous stratification by age, sex, and race or
ethnicity. Furthermore, these cross-sectional observational
data cannot provide definitive information about the cost
benefit of CAC measurement.
Conclusions
Our study showed that in a large, multiethnic, multicenter,
community-based cohort of men and women, CAC preva-
lence was associated closely with FRS strata after multivar-
iate analysis regardless of age, sex, or race or ethnicity. It
suggests a low probability of having a high CAC score in the
very low-risk population with FRS of 5%. Consequently,
the yield of screening for advanced CAC burden (CAC
300) is lesser in this population of very low-risk persons,but seems to be higher in low- to intermediate-risk indi-
viduals with FRS of 5.1% to 20.0%.
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